M0_/|WTG>R62B9>+MJMV|PVPTEZ3ZL/E?W
SYSTEM PROCESSING...
M0_/|WTG>R62B9>+MJMV|PVPTEZ3ZL/E?W
SYSTEM PROCESSING...
Posted: 2025-04-23 07:09:01 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-23 07:09:27 UTC
Verified By
Rollup News
Aripiprazole is a partial agonist at the dopamine D2 receptor, offering bidirectional regulation of dopaminergic tone. It increases dopamine in low-dopamine states and reduces excessive activity in high-dopamine states, helping to minimize both positive and negative symptoms in schizophrenia. It also acts on multiple receptors, including 5HT1A, 5HT2A, and 5HT7, contributing to anxiolytic, antidepressant, and cognitive benefits. Aripiprazole has a long half-life, supporting once-daily dosing and improving adherence. It is approved for schizophrenia, bipolar I disorder, major depressive disorder, irritability associated with autism spectrum disorder, and Tourette’s disorder. Aripiprazole carries a low risk of extrapyramidal side effects and hyperprolactinaemia, and minimal impact on metabolic parameters.
Aripiprazole's partial agonism at D2 receptors allows for targeted dopamine modulation.
It acts as a dimmer switch, turning up dopamine when it's too low and turning it down when it's too high.
It has a broader receptor profile, acting on D2, 5HT1A, 5HT2A, and 5HT7 receptors.
It has a long half-life, supporting once-daily dosing and improving adherence.
It is approved for a variety of disorders, including schizophrenia, bipolar I disorder, and major depressive disorder.
May cause akathisia, particularly early in treatment.
Less sedating than other SGAs, potentially causing activation in some patients.
Individual variability in response due to CYP2D6/CYP3A4 metabolism.
Careful cross-tapering is required when switching from full antagonists to avoid dopaminergic rebound.